Tumor burden talks in cancer treatment with PEGylated liposomal drugs.
PURPOSE: PEGylated liposomes are important drug carriers that can passively target tumor by enhanced permeability and retention (EPR) effect in neoplasm lesions. This study demonstrated that tumor burden determines the tumor uptake, and also the tumor response, in cancer treatment with PEGylated lip...
Main Authors: | Yi-Yu Lin, Hao-Wen Kao, Jia-Je Li, Jeng-Jong Hwang, Yun-Long Tseng, Wuu-Jyh Lin, Ming-Hsien Lin, Gann Ting, Hsin-Ell Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3651236?pdf=render |
Similar Items
-
A tale of the two PEGylated liposomal doxorubicins
by: Chou HH, et al.
Published: (2015-07-01) -
PEGylated liposomes: immunological responses
by: Marwa Mohamed, et al.
Published: (2019-12-01) -
Pegylated liposomal doxorubicin in ovarian cancer
by: Robert Strother, et al.
Published: (2009-08-01) -
Evidence of Protein Adsorption in Pegylated Liposomes: Influence of Liposomal Decoration
by: Marc Sangrà, et al.
Published: (2017-02-01) -
Preparation and Evaluation of PEGylated and Folate-PEGylated Liposomes Containing Paclitaxel for Lymphatic Delivery
by: Hea-Young Cho, et al.
Published: (2015-01-01)